A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. [electronic resource]
Producer: 20070206Description: 817-24 p. digitalISSN:- 1744-6872
- Adenocarcinoma -- diagnosis
- Adult
- Aged
- Antimetabolites, Antineoplastic -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols
- Chemotherapy, Adjuvant
- Combined Modality Therapy
- Female
- Fluorouracil -- therapeutic use
- Genotype
- Haplotypes
- Humans
- Male
- Methylenetetrahydrofolate Reductase (NADPH2) -- genetics
- Middle Aged
- Neoplasm Staging
- Polymorphism, Genetic
- Prognosis
- Radiation Dosage
- Radiotherapy, Adjuvant
- Rectal Neoplasms -- diagnosis
- Remission Induction
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.